全文获取类型
收费全文 | 37180篇 |
免费 | 3464篇 |
国内免费 | 2635篇 |
专业分类
耳鼻咽喉 | 399篇 |
儿科学 | 464篇 |
妇产科学 | 409篇 |
基础医学 | 4303篇 |
口腔科学 | 626篇 |
临床医学 | 5028篇 |
内科学 | 5441篇 |
皮肤病学 | 401篇 |
神经病学 | 2162篇 |
特种医学 | 1363篇 |
外国民族医学 | 24篇 |
外科学 | 3528篇 |
综合类 | 6772篇 |
现状与发展 | 11篇 |
预防医学 | 2346篇 |
眼科学 | 1162篇 |
药学 | 3812篇 |
31篇 | |
中国医学 | 2011篇 |
肿瘤学 | 2986篇 |
出版年
2024年 | 139篇 |
2023年 | 730篇 |
2022年 | 1716篇 |
2021年 | 1972篇 |
2020年 | 1514篇 |
2019年 | 1301篇 |
2018年 | 1365篇 |
2017年 | 1273篇 |
2016年 | 1125篇 |
2015年 | 1717篇 |
2014年 | 2064篇 |
2013年 | 1842篇 |
2012年 | 2838篇 |
2011年 | 2931篇 |
2010年 | 1777篇 |
2009年 | 1426篇 |
2008年 | 1734篇 |
2007年 | 1796篇 |
2006年 | 1820篇 |
2005年 | 1813篇 |
2004年 | 1191篇 |
2003年 | 1106篇 |
2002年 | 975篇 |
2001年 | 828篇 |
2000年 | 837篇 |
1999年 | 965篇 |
1998年 | 624篇 |
1997年 | 679篇 |
1996年 | 507篇 |
1995年 | 428篇 |
1994年 | 365篇 |
1993年 | 218篇 |
1992年 | 288篇 |
1991年 | 260篇 |
1990年 | 222篇 |
1989年 | 192篇 |
1988年 | 176篇 |
1987年 | 147篇 |
1986年 | 109篇 |
1985年 | 91篇 |
1984年 | 40篇 |
1983年 | 25篇 |
1982年 | 32篇 |
1981年 | 16篇 |
1980年 | 11篇 |
1979年 | 11篇 |
1972年 | 4篇 |
1971年 | 7篇 |
1966年 | 3篇 |
1940年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
目的探讨1 470 nm激光剜除治疗高危前列腺增生的手术技巧及临床效果。
方法回顾分析2018年6月至2018年9月中山大学附属第三医院泌尿外科采用1 470 nm激光治疗共89例高危前列腺增生患者的临床资料,年龄平均(68±3)岁,前列腺体积(57.4±2.6)ml。所有患者均采用"寻找层面,先易后难,剜切结合"的层面递进法思路行激光腔内前列腺剜除术,比较患者术中及术后情况。
结果89例均顺利完成手术,与术前相比,术后3个月患者最大尿流率明显增加,[(6.9±2.1) ml/s vs(19.8±3.6) ml/s]。国际前列腺症状评分显著好转,[(24.6±1.7) vs(8.0±1.2)]。术中无输血、无电切综合征、无直肠和膀胱穿孔病例,无输尿管损伤、大出血、心脑血管意外等严重并发症发生。
结论层面递进法激光剜除技术构想对于高危前列腺增生外科包膜层面的寻找、减少术后并发症有独到优势,且易于掌握,或可为业界同行提供一个新的思路。 相似文献
13.
14.
15.
16.
Qianlai Luo Jonathan N. Hofmann Ruth M. Pfeiffer Cari M. Kitahara Minkyo Song Meredith S. Shiels 《International journal of cancer. Journal international du cancer》2023,153(1):64-72
In the United States, renal cell carcinoma (RCC) incidence and the prevalence of obesity, an established risk factor for RCC, have been increasing for several decades. RCC is more common among older individuals. We sought to quantify the contribution of excess adiposity to the rising incidence of RCC among individuals 60 years or older. National Institutes of Health-American Association of Retired Persons Diet and Health Study data (n = 453 859 participants, enrolled in 1995-1996, age at enrollment 50-71 years) were used to estimate multivariable-adjusted hazard ratios (HRs) for RCC across body mass index categories and HRs associated with smoking. Population attributable fractions (PAFs) were calculated using estimated HRs and annual overweight/obesity prevalence from the National Health Interview Survey (1985-2008). PAF estimates were combined with RCC incidence from Surveillance, Epidemiology and End Results-13 to calculate annual percent changes in RCC incidence attributable (and unrelated) to overweight/obesity. We found that between 1995 and 2018, among individuals aged 60 years and older, PAF for overweight/obesity increased from 18% to 29% for all RCCs. In comparison, the PAF for smoking declined from 12% to 9%. RCC incidence increased 1.8% per year (95% confidence interval [CI] 1.5%-2.1%) overall, while RCC incidence attributable to overweight/obesity increased 3.8% per year (95%CI 3.5%-4.2%) and RCC incidence unrelated to overweight/obesity increased 1.2% per year (95% CI 0.9%-1.4%). In conclusion, overweight/obesity appears to have contributed importantly to the rising incidence of RCC in the United States since the mid-1990s. Public health interventions focused on reducing overweight and obesity could help substantially in curbing this trend. 相似文献
17.
18.
19.
关节假体周围感染(periprosthetic joint infection,PJI)是人工关节置换术后可能发生的一种严重并发症,其导致的严重后果,无论对于医生还是患者来说,都很难接受。目前,由于多种不确定因素的存在,PJI诊断的准确性较低。传统的血清学检查、影像学检查有一定的价值,但是易受全身情况的影响,导致特异性不高。为了正确诊断关节假体周围感染,不同学科的研究人员采用各种不同的方法进行了大量的诊断研究,并取得了丰富的成果。近年来,关节滑液炎性标志物检测、分子生物学方法等被研究证实具有较高的敏感性和特异性。因此,关节滑液CRP、-防御素、白细胞酯酶、PCR技术等被广泛研究,期望能从中找到诊断关节假体周围感染的特异性指标,提高临床诊断的准确性。 相似文献
20.
Calculus bovis is commonly used for the treatment of stroke in traditional Chinese medicine. Hyodeoxycholic acid(HDCA) is a bioactive compound extracted from calculus bovis. When combined with cholic acid, baicalin and jas-minoidin, HDCA prevents hypoxia-reoxygenation-induced brain injury by suppressing endoplasmic reticulum stress-mediated apoptotic signaling. However, the effects of HDCA in ischemic stroke injury have not yet been studied. Neurovascular unit(NVU) dysfunction occurs in ischemic stroke. Therefore, in this study, we investigated the effects of HDCA on the NVU under ischemic conditions in vitro. We co-cultured primary brain microvascular endothelial cells, neurons and astrocytes using a transwell chamber co-culture system. The NVU was pre-treated with 10.16 or 2.54 μg/mL HDCA for 24 hours before exposure to oxygen-glucose deprivation for 1 hour. The cell counting kit-8 assay was used to detect cell activity. Flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling were used to assess apoptosis. Enzyme-linked immunosorbent assay was used to measure the expression levels of inflammatory cytokines, including interleukin-1β, interleukin-6 and tumor necrosis factor-α, and neurotrophic factors, including brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. Oxidative stress-related factors, such as superoxide dismutase, nitric oxide, malondialdehyde and γ-glutamyltransferase, were measured using kits. Pretreatment with HDCA significantly decreased blood-brain barrier permeability and neuronal apoptosis, significantly increased transendothelial electrical resistance and γ-glutamyltransferase activity, attenuated oxidative stress damage and the release of inflammatory cytokines, and increased brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression. Our findings suggest that HDCA maintains NVU morphological integrity and function by modulating inflammation, oxidation stress, apoptosis, and the expression of neurotrophic factors. Therefore, HDCA may have therapeutic potential in the clinical management of ischemic stroke. This study was approved by the Ethics Committee of Experimental Animals of Beijing University of Chinese Medicine(approval No. BUCM-3-2016040201-2003) in April 2016. 相似文献